Literature DB >> 23615011

Extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults.

Kelly E Williams1.   

Abstract

Despite advances in treatment, acute respiratory distress syndrome (ARDS) remains a common cause of respiratory failure requiring ventilatory support and is associated with significantly high rates of morbidity and mortality. To date, the only treatment shown to increase survival rate in patients with ARDS is the use of supportive mechanical ventilation using low tidal volumes. Extracorporeal membrane oxygenation (ECMO) is a therapy that has been used in severe cases of ARDS when patients fail to improve with traditional management. Recent literature shows varying mortality rates for the use of ECMO for ARDS; however, the literature suggests that transfer of patients to an ECMO center for treatment using specific criteria and indications may improve outcomes. Further research is needed regarding the timing of the initiation of ECMO, standardization of therapy, and which type of ECMO reduces morbidity and mortality rates in patients with ARDS.

Entities:  

Mesh:

Year:  2013        PMID: 23615011     DOI: 10.1097/NCI.0b013e31828a09ff

Source DB:  PubMed          Journal:  AACN Adv Crit Care        ISSN: 1559-7768


  3 in total

1.  Amniotic Fluid Embolism: Using the Medical Staff Process to Facilitate Streamlined Care.

Authors:  Peter M Hession; Cynthia J Millward; Joyce E Gottesfeld; Thomas F Rehring; Kevin B Miller; Paul M Chetham; S Kel Muckleroy; Christopher A Bates; Harris W Hollis
Journal:  Perm J       Date:  2016-08-17

Review 2.  Mechanical Ventilation during Extracorporeal Membrane Oxygenation in Patients with Acute Severe Respiratory Failure.

Authors:  Zhongheng Zhang; Wan-Jie Gu; Kun Chen; Hongying Ni
Journal:  Can Respir J       Date:  2017-01-03       Impact factor: 2.409

3.  Practices in Triage and Transfer of Critically Ill Patients: A Qualitative Systematic Review of Selection Criteria.

Authors:  Joseph Dahine; Paul C Hébert; Daniela Ziegler; Noémie Chenail; Nicolay Ferrari; Réjean Hébert
Journal:  Crit Care Med       Date:  2020-11       Impact factor: 9.296

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.